AliHealth unifies the command of B2C and O2O pharmaceutical businesses, completing the instant retail puzzle.

```

Alibaba is bringing together its pharmaceutical retail capabilities, which were originally scattered across different business systems.

On May 15, Shen Difan, Chairman of the Board and CEO of Alibaba Health, revealed at the FY2026 earnings call with analysts that Alibaba Health will unify command of the pharmaceutical business units under the “B2C+O2O” model to achieve close collaboration and synergy.

Shen Difan stated that within the group, dedicated teams have been established for the pharmaceutical businesses in the B2C and O2O flash sales units, all under the unified direction of Alibaba Health. “We will meet consumers’ health needs in various scenarios.”

This means that the previously segmented pharmaceutical e-commerce and instant retail pharmaceutical businesses within the Alibaba ecosystem are now entering a phase of unified management.

For Alibaba Health, this also fills gaps in its business boundaries amid intensifying competition in instant retail for pharmaceuticals.

In the past, Alibaba Health’s strengths were mainly centered in pharmaceutical B2C scenarios, where users purchased medicines, health supplements, and medical devices on Taobao, primarily catering to planned, stockpiling, and chronic disease repurchase needs.

However, O2O pharmaceutical business was mostly concentrated in the flash sales sector, emphasizing supply from nearby pharmacies, hour-level fulfillment, and emergency medication needs.

These two types of business previously seemed to serve different scenarios, but now their boundaries are becoming increasingly blurred. Especially in the health segment, chronic disease repurchase, household medicine stock, and health supplement consumption are not necessarily planned e-commerce purchases; they could also happen in instant delivery scenarios.

JD Health and Meituan Medicine have already advanced along this path.

JD Health leverages JD's main site for online pharmaceutical demand, while also connecting offline pharmacies to instant delivery networks through services like “JD Medicine Express” and “Medicine Hour Delivery,” integrating distant shelf e-commerce with near-field instant fulfillment.

Meituan Medicine entered earlier through local lifestyle scenarios, using a 24-hour digital pharmacy and instant delivery system to connect offline pharmacy supply to online traffic.

In this competitive landscape, Alibaba Health’s past weakness was the lack of full integration between B2C and O2O.

As instant retail ecosystems such as Taobao Flash Sales rise in importance within Alibaba, pharmaceuticals—being a high-frequency, essential, and service-extensible category—are becoming a key segment that Alibaba Health must restructure.

According to Shen Difan, after the “unified command” strategy is implemented, Alibaba Health can use the B2C and O2O flash sales systems to gain insight into refined health needs across tens of thousands of grids nationwide and provide more accurate and practical traceability and digital services to pharmaceutical companies.

Overall, competition in pharmaceutical retail is no longer just about price and categories between online pharmacies, but about whether platforms can consistently reach users, understand them, and provide professional services across different health scenarios.

Alibaba Health’s current unification of pharmaceutical business is an attempt to reorganize past capabilities that were dispersed across various portals and scenarios into a more complete health consumption network.

Risk Warning and Disclaimer ClauseThe market has risks, and investment needs to be cautious. This article does not constitute personal investment advice and does not take into consideration individual users’ special investment objectives, financial situations, or needs. Users should consider whether any opinions, viewpoints, or conclusions in this article are suitable for their specific circumstances. Investing based on this article is at your own risk. ```